- Why it’s recommended : Dr. Lal PathLabs Ltd is a leading Indian diagnostic and healthcare service provider. It offers a broad catalogue of over 5,000 diagnostic tests. The prices have been continuously taking support at the Tenkan Sen and Kijun Sen and driving higher. Now with the Relative Strength Index shows that the prices have moved beyond important threshold showing signs of recovery has seen a swift upside indicating some upward trajectory. Look to go long.
- Key metrics:
- P/E Ratio : 57.40,
- 52-week high: ₹1803.60,
- Volume: 385.08K.
- Technical analysis: Support at ₹1600, resistance at ₹1950.
- Risk factors: Primarily pricing pressure, shifting labor codes, competitive intensity, and a heavy reliance on its traditional hub-and-spoke model.
- Buy : above ₹1750
- Stop loss: ₹1675
- Target price: ₹1900 (2 Months)
Stock market recap
Broader indices struggled, with midcaps down 0.4% and smallcaps losing 1%. Realty, PSU banks, autos, and IT led sectoral declines, while pharma and metals provided some relief with modest gains. HCL Tech, Shriram Finance, HDFC Life, Tata Motors, and Interglobe Aviation were among the top losers, while Bharti Airtel, Apollo Hospitals, Sun Pharma, TCS, and Dr Reddy’s stood out as gainers.
About The Author
